Oncternal Therapeutics, Inc.
ONCTDelisted Mar 17, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001260990
Oncternal Therapeutics, Inc. was delisted on Mar 17, 2025; its insiders filed their last Form 4 on Jun 24, 2024; 23 institutions reported holding it in 13F filings for Q3 2024, worth $471.0K in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Oncternal Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Oncternal Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Hale David F | Director | 29,673Indirect | Jun 24, 2024 | 0 |
| Kisner Daniel L | Director | – | Jun 24, 2024 | 0 |
| Larue William R | Director | – | Jun 24, 2024 | 0 |
| Carter Michael G | Director | – | Jun 24, 2024 | 0 |
| Mazanet Rosemary | Director | – | Jun 24, 2024 | 0 |
| Theuer Charles | Director | – | Jun 24, 2024 | 0 |
| Wills Robert James | Director | 10,000 | Jun 24, 2024 | 0 |
| DeSimone Jill | Director | – | Jun 24, 2024 | 0 |
| Breitmeyer James B | Chief Executive Officer | 15,426Indirect | Feb 15, 2024 | 0 |
| Vincent Richard G | Chief Financial Officer | 140,922 | Feb 15, 2024 | 0 |
| Leavitt Chase C. | General Counsel/Secretary | 84,758 | Feb 15, 2024 | 0 |
| Yazji Salim | Chief Medical Officer | 128,635 | Feb 15, 2024 | 0 |
| Krishnan Rajesh | CTO/CSO | 44,019 | Feb 15, 2024 | 0 |
| Nakanishi Xin | Director | – | Jun 30, 2023 | 0 |
| Kaufmann Gunnar F. | Chief Scientific Officer | 94,726 | Jun 14, 2023 | 0 |
| Chen Jinzhu PhD | Director | – | Jun 17, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 2, 2021 (view filing) | Jun 30 | 2 days | Hale David FDirector | SSale | −3.67K | $4.75 | −$17.4K | −0.5%713.2K after | |
| Jan 31, 2022 (view filing) | Jan 27 | 4 days | Breitmeyer James BChief Executive Officer | PPurchase | +25.0K | $1.68 | +$42.0K | +116.0%46.5K after | |
| Jan 31, 2022 (view filing) | Jan 27 | 4 days | Yazji SalimChief Medical Officer | PPurchase | +10.0K | $1.69 | +$16.9K | +17.5%67.1K after | |
| Jan 31, 2022 (view filing) | Jan 27-28 | 4 days | Leavitt Chase C.General Counsel/Secretary | PPurchase | +13.5K | $1.72 | +$23.3K | +43.0%44.9K after | 2 lots |
| Jan 31, 2022 (view filing) | Jan 27-28 | 4 days | Vincent Richard GChief Financial Officer | PPurchase | +12.5K | $1.73 | +$21.6K | +17.7%83.2K after | 3 lots |
| Mar 28, 2022 (view filing) | Mar 24-28 | 4 days | Vincent Richard GChief Financial Officer | PPurchase | +5.00K | $1.44 | +$7.21K | +6.0%88.2K after | 5 lots |
| Apr 14, 2023 (view filing)6:00 AM ET | Apr 13 | 1 day | Vincent Richard GChief Financial Officer | PPurchase | +30.0K | $0.2987 | +$8.96K | +23.6%156.9K after | |
| Apr 14, 2023 (view filing)6:00 AM ET | Apr 12-13 | 2 days | Leavitt Chase C.General Counsel/Secretary | PPurchase | +25.0K | $0.29 | +$7.25K | +30.5%106.9K after | 2 lots |
| Apr 14, 2023 (view filing)6:02 PM ET | Apr 12-14 | 2 days | Yazji SalimChief Medical Officer | PPurchase | +25.0K | $0.288 | +$7.20K | +17.9%164.7K after | 3 lots |
| Apr 17, 2023 (view filing)6:00 AM ET | Apr 13-14 | 4 days | Breitmeyer James BChief Executive Officer | PPurchase | +150.0K | $0.2929 | +$43.9K | +322.3%196.5K after | 3 lots |
| Jun 14, 2023 (view filing)4:00 PM ET | Jun 12-14 | 2 days | Kaufmann Gunnar F.Chief Scientific Officer | PPurchase | +28.0K | $0.3509 | +$9.82K | +42.0%94.7K after | 2 lots |
| Feb 27, 2024 (view filing) | Feb 23 | 4 days | Wills Robert JamesDirector | SSale | −980 | $9.04 | −$8.86K | −100.0%0 after | |
| Feb 27, 2024 (view filing) | Feb 23 | 4 days | Hale David FDirector | PPurchase | +714 | $9.04 | +$6.45K | New position714 after | |
| Feb 27, 2024 (view filing) | Feb 23 | 4 days | Hale David FDirector | PPurchase | +266 | $9.04 | +$2.40K | +0.9%29.7K after | |
| Apr 1, 2024 (view filing) | Mar 28 | 4 days | Wills Robert JamesDirector | PPurchase | +6.91K | $8.48 | +$58.6K | New position6.91K after | |
| Apr 10, 2024 (view filing) | Apr 8 | 2 days | Wills Robert JamesDirector | PPurchase | +3.09K | $8.96 | +$27.7K | +44.6%10.0K after |